{"title":"乳腺极性颠倒的高细胞癌的临床病理特征:病例报告和文献综述。","authors":"Ines Houissa, Yoldez Houcine, Amira Hmidi, Hanène Bouaziz, Tarek Dieb, Maha Driss","doi":"10.1016/j.ijscr.2024.110444","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Tall cell carcinoma of the breast with reverse polarity (TCCRP) is a recently described rare entity with low potential for malignancy which exhibits morphological features with tall cell variant of papillary thyroid carcinoma. Immunohistochemical and molecular studies help establish the diagnosis.</p><p><strong>Case report: </strong>We report the case of a 45-year-old woman with no significant medical or surgical history who presented with mastodynia. Physical examination was negative. Screening by bilateral mammography revealed a mass of the right breast which was classified as 4B. The mass was surgically excised. The pathological report concluded to a TCCRP of the breast with free margins. The tumor cells were negative for hormone receptors as well as for the Human Epidermal Growth Factor Receptor-2 (HER2neu). The patient underwent a sentinel lymph node dissection that was negative followed by loco-regional radiotherapy. Chemotherapy and endocrine therapy were not indicated for the patient. After 24 months of follow-up, no signs of loco-regional or distant recurrences have been identified.</p><p><strong>Clinical discussion: </strong>TCCRP is a rare entity that has been recently introduced in the WHO classification of breast cancer. It is usually a triple negative tumor, negative to TTF1 and thyroglobulin with low proliferation index, and a low potential for malignancy. Wide excision is the keystone of the treatment; however, chemotherapy and radiotherapy are still controversial due to lack of evidence.</p><p><strong>Conclusion: </strong>TCCRP is a rare entity, which carries an excellent prognosis. A proper diagnosis is essential to conduct the best treatment next to a careful follow-up due to the ambiguous natural history of this rare entity.</p><p><strong>Papers that have been previously published as meeting abstracts: </strong>None.</p>","PeriodicalId":48113,"journal":{"name":"International Journal of Surgery Case Reports","volume":null,"pages":null},"PeriodicalIF":0.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539130/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinicopathological characterization of tall cell carcinoma with reversed polarity of the breast: A case report and review of the litterature.\",\"authors\":\"Ines Houissa, Yoldez Houcine, Amira Hmidi, Hanène Bouaziz, Tarek Dieb, Maha Driss\",\"doi\":\"10.1016/j.ijscr.2024.110444\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Tall cell carcinoma of the breast with reverse polarity (TCCRP) is a recently described rare entity with low potential for malignancy which exhibits morphological features with tall cell variant of papillary thyroid carcinoma. Immunohistochemical and molecular studies help establish the diagnosis.</p><p><strong>Case report: </strong>We report the case of a 45-year-old woman with no significant medical or surgical history who presented with mastodynia. Physical examination was negative. Screening by bilateral mammography revealed a mass of the right breast which was classified as 4B. The mass was surgically excised. The pathological report concluded to a TCCRP of the breast with free margins. The tumor cells were negative for hormone receptors as well as for the Human Epidermal Growth Factor Receptor-2 (HER2neu). The patient underwent a sentinel lymph node dissection that was negative followed by loco-regional radiotherapy. Chemotherapy and endocrine therapy were not indicated for the patient. After 24 months of follow-up, no signs of loco-regional or distant recurrences have been identified.</p><p><strong>Clinical discussion: </strong>TCCRP is a rare entity that has been recently introduced in the WHO classification of breast cancer. It is usually a triple negative tumor, negative to TTF1 and thyroglobulin with low proliferation index, and a low potential for malignancy. Wide excision is the keystone of the treatment; however, chemotherapy and radiotherapy are still controversial due to lack of evidence.</p><p><strong>Conclusion: </strong>TCCRP is a rare entity, which carries an excellent prognosis. A proper diagnosis is essential to conduct the best treatment next to a careful follow-up due to the ambiguous natural history of this rare entity.</p><p><strong>Papers that have been previously published as meeting abstracts: </strong>None.</p>\",\"PeriodicalId\":48113,\"journal\":{\"name\":\"International Journal of Surgery Case Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539130/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Surgery Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ijscr.2024.110444\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/13 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Surgery Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ijscr.2024.110444","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/13 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
摘要
导言:具有反向极性的乳腺高细胞癌(TCCRP)是最近描述的一种罕见病例,其恶性可能性较低,具有甲状腺乳头状癌高细胞变异的形态学特征。免疫组化和分子研究有助于确诊:我们报告了一例 45 岁女性的病例,她没有明显的内外科病史,却出现了乳房胀痛。体格检查呈阴性。双侧乳房 X 光检查发现右侧乳房有一肿块,被列为 4B。手术切除了肿块。病理报告结果为乳腺 TCCRP,边缘游离。肿瘤细胞的激素受体和人类表皮生长因子受体-2(HER2neu)均为阴性。患者接受了前哨淋巴结清扫术,结果为阴性,随后接受了局部区域放疗。化疗和内分泌治疗不适用于该患者。经过24个月的随访,没有发现局部或远处复发的迹象:临床讨论:TCCRP是一种罕见的肿瘤,最近才被纳入世界卫生组织的乳腺癌分类中。它通常为三阴性肿瘤,TTF1和甲状腺球蛋白阴性,增殖指数低,恶性可能性小。广泛切除是治疗的关键,但由于缺乏证据,化疗和放疗仍存在争议:结论:TCCRP 是一种罕见病,预后良好。结论:TCCRP 是一种罕见疾病,预后极佳。由于这种罕见疾病的自然病史不明确,因此正确诊断是进行最佳治疗和仔细随访的关键:无。
Clinicopathological characterization of tall cell carcinoma with reversed polarity of the breast: A case report and review of the litterature.
Introduction: Tall cell carcinoma of the breast with reverse polarity (TCCRP) is a recently described rare entity with low potential for malignancy which exhibits morphological features with tall cell variant of papillary thyroid carcinoma. Immunohistochemical and molecular studies help establish the diagnosis.
Case report: We report the case of a 45-year-old woman with no significant medical or surgical history who presented with mastodynia. Physical examination was negative. Screening by bilateral mammography revealed a mass of the right breast which was classified as 4B. The mass was surgically excised. The pathological report concluded to a TCCRP of the breast with free margins. The tumor cells were negative for hormone receptors as well as for the Human Epidermal Growth Factor Receptor-2 (HER2neu). The patient underwent a sentinel lymph node dissection that was negative followed by loco-regional radiotherapy. Chemotherapy and endocrine therapy were not indicated for the patient. After 24 months of follow-up, no signs of loco-regional or distant recurrences have been identified.
Clinical discussion: TCCRP is a rare entity that has been recently introduced in the WHO classification of breast cancer. It is usually a triple negative tumor, negative to TTF1 and thyroglobulin with low proliferation index, and a low potential for malignancy. Wide excision is the keystone of the treatment; however, chemotherapy and radiotherapy are still controversial due to lack of evidence.
Conclusion: TCCRP is a rare entity, which carries an excellent prognosis. A proper diagnosis is essential to conduct the best treatment next to a careful follow-up due to the ambiguous natural history of this rare entity.
Papers that have been previously published as meeting abstracts: None.